Aktuellt
SENASTE
Overall, Q2 was an eventful quarter for BB Biotech’s portfolio in terms of clinical trial read outs and regulatory news, leading to portfolio reallocations. The quarter ended with BB Biotech shares being priced at a 5% discount relative to its NAV, though the share is now back to trading at a premium lower than the historical average. There might still be attractive returns on horizon. The BoD has applied for a delisting of BB Biotech’s shares from Borsa Italiana.
LÄS MER
